Search PubMed⌕ Search

Biomedical subjects

Y Lerner

Publications and source records attributed to Y Lerner.

45 records · Page 3Linked to original sources
PubMed1988

Lithium combined with haloperidol in schizophrenic patients.

Previously, the addition of lithium to haloperidol has been reported to be of modest benefit to schizoaffective patients. To test this treatment on a different sample, 36 mainly schizophrenic patients were subdivided on the basis of the median of their initial depression score on the BPRS into depressive and non-depressive schizophrenic subjects. Each group randomly received haloperidol plus placebo or haloperidol plus lithium for 8 weeks. The schizophrenic patients who were on the depressive side of the median BPRS depression score were found to be the most resistant to neuroleptic treatment alone, and benefited from the addition of lithium.

Adolescent↗
PubMed1985

Depressive symptoms in acute schizophrenic hospitalized patients.

Thirty-four newly admitted patients who met the Research Diagnostic Criteria for schizophrenia were assessed on admission and in their 8th week of hospitalization. The data were obtained using the Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HAM-D), and the Extrapyramidal Involvement Rating Scale (EPRS). A significant reduction in BPRS scores was observed on Week 8 scores compared with baseline scores (p less than .001); however, no significant difference could be found between baseline and Week 8 HAM-D scores. In addition, no significant correlation between the HAM-D scores and the EPRS scores was seen. Depressive symptoms appear to be present during the acute phase of schizophrenic psychosis and do not remit as rapidly as the psychotic symptoms.

Acute Disease↗
PubMed1982

Treating Israeli Soldiers in a civilian psychiatric setting.

The structure, functioning, and treatment concept of a psychodynamically oriented psychiatric unit for young soldiers within Israeli civilian hospital are discussed stressing: (1) the integration of the patient's military self; (2) the resolution of psychological conflicts necessary to avoid traumatic developmental arrest of the patient's personality and to foster personality growth; (3) the involvement of the patient's family in the therapeutic process. Problems in the patient-therapist relationship specifically pertaining to Israeli conditions are outlined.

Adolescent↗
PubMed1981

A symptom profile analysis of antipsychotic drug treatment: nonparametric multidimensional technique.

Thirty-six schizoaffective patients were treated with haloperidol plus lithium or haloperidol plus placebo. Standard statistical analysis showed greater improvement in those treated with lithium plus haloperidol, as published previously. The Brief Psychiatric Rating Scale (BPRS) scores were reanalyzed in the present study using a nonparametric technique for multidimensional scaling of symptom profiles. The differential outcome after haloperidol with or without added lithium is determined both by symptom dimension and by type of drug. Added lithium prevents a depressive shift after haloperidol treatment on the dimension of "cognitive disorganization--depressive preoccupation."

Drug Combinations↗
PubMed1979

Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study.

Lithium carbonate alone has been shown to be inferior to neuroleptics alone in the treatment of excited schizo-affective illness. However, in clinical practice, lithium carbonate and neuroleptics are often combined in this disorder. We report a double-blind five-week controlled trial of lithium carbonate plus haloperidol vs placebo plus haloperidol in the treatment of excited schizo-affective patients. Eighteen patients were studied in each treatment group. Modest but statistically significant differences in favor of lithium carbonate plus haloperidol were found by week 5, using the Brief Psychiatric Rating Scale. Lithium carbonate plus haloperidol was favored both for affective schizo-affectives and for schizophrenic schizo-affectives. Lithium carbonate benefit did not seem to be restricted to affective symptoms only. In the clinical treatment of acute schizo-affective illness, the modest benefits of added lithium carbonate must be weighed against the risks of the drug's toxicity.

Adult↗
PubMed1979

Acute high-dose parenteral haloperidol treatment of psychosis.

After 2 days of drug-free observation, 20 newly admitted psychotic patients received 20-35 mg of haloperidol intravenously and 20 patients received 30-40 mg of diazepam intravenously. Posttreatment ratings at 4 and 24 hours with the Brief Psychiatric Rating Scale and the Clinical Global Impressions revealed significant improvement in both groups but no significant differences between the two treatments.

Acute Disease↗